Manal F. Abdelmalek, MD

Professor of Medicine
Campus mail 03119 Hosp South, Suite 03107, Room 03125, Durham, NC 27710
Phone (919) 684-3262
Email address manal.abdelmalek@duke.edu

My research interests include metabolic liver disease, particularly obesity-related liver disease and its association with complications of the insulin resistance syndrome. I am interested in studying the clinical, environmental, and genetic risk factors for nonalcoholic fatty liver disease, new therapeutic options for treatment, and evaluating the impact of NAFLD from a public health perspective.

In Their Words

Education and Training

  • Fellow in Gastroenterology, Medicine, Mayo School of Health Sciences, 1995 - 1998
  • Medical Resident, Medicine, Mayo School of Health Sciences, 1992 - 1995
  • M.D., University Missouri Kansas City, 1992

Publications

Moylan, CA, and Abdelmalek, MF. "Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis." Hepatology (Baltimore, Md.) 68, no. 4 (October 2018): 1646-1648.

PMID
29534302
Full Text

Moylan, CA, Sorrow, PA, Mavis, A, Bashir, M, Jima, D, Maguire, R, Bozdogan, E, Buie, S, Murphy, SK, Diehl, AM, Hoyo, C, and Abdelmalek, MF. "Obesity and Nonalcoholic Fatty Liver Disease in Childhood Associate with Altered DNA Methylation in Early Life." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Harrison, SA, Abdelmalek, MF, Caldwell, S, Shiffman, ML, Diehl, AM, Ghalib, R, Lawitz, EJ, Rockey, DC, Schall, RA, Jia, C, McColgan, BJ, McHutchison, JG, Subramanian, GM, Myers, RP, Younossi, Z, Ratziu, V, Muir, AJ, Afdhal, NH, Goodman, Z, Bosch, J, Sanyal, AJ, and GS-US-321-0105 and GS-US-321-0106 Investigators, . "Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis." Gastroenterology 155, no. 4 (October 2018): 1140-1153.

PMID
29990488
Full Text

Abdelmalek, MF, Freilich, BL, Harrison, SA, Powell, EE, Rinella, MEM, Tobis, N, Peres, D, Kanellos, J, Lalazar, G, and Sanyal, AJ. "Imm-124E Improves Metabolic Endotoxemia and Markers of Liver Injury in Nonalcoholic Steatohepatitis." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Abdelmalek, MF, Freilich, BL, Harrison, SA, Powell, EE, Rinella, MEM, Tobis, N, Peres, D, Kanellos, J, Lalazar, G, and Sanyal, AJ. "Imm-124E Improves Metabolic Endotoxemia and Markers of Liver Injury in Nonalcoholic Steatohepatitis." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Neuschwander-Tetri, BA, Kowdley, KV, Sanyal, AJ, Abdelmalek, MF, Terrault, N, McCullough, AJ, Wang, P, Shringarpure, R, MacCone, L, Shapiro, DA, and Loomba, R. "Efficacy and Safety of Obeticholic Acid in Patients with Non-Alcoholic Steatohepatitis and Significant Fibrosis Using Endpoint Definitions and Populations Accepted for Registrational Studies." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Neuschwander-Tetri, BA, Kowdley, KV, Sanyal, AJ, Abdelmalek, MF, Terrault, N, McCullough, AJ, Wang, P, Shringarpure, R, MacCone, L, Shapiro, DA, and Loomba, R. "Efficacy and Safety of Obeticholic Acid in Patients with Non-Alcoholic Steatohepatitis and Significant Fibrosis Using Endpoint Definitions and Populations Accepted for Registrational Studies." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Abdelmalek, MF, Lanthier, N, Chojkier, M, Kluwe, J, Fowell, AJ, Yuan, J, Nicandro, JP, Seyedkazemi, S, Fischer, L, Goodman, ZD, and Harrison, SA. "Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Abdelmalek, MF, Lanthier, N, Chojkier, M, Kluwe, J, Fowell, AJ, Yuan, J, Nicandro, JP, Seyedkazemi, S, Fischer, L, Goodman, ZD, and Harrison, SA. "Cenicriviroc Treatment over 2 Years Results in Clinically Meaningful and Sustained Improvement in Fibrosis in Adults with Nonalcoholic Steatohepatitis and Severe Liver Fibrosis." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Chaudhry, M, Moylan, CA, Middleton, MS, Farjat, A, Chaudhury, KR, Guy, CD, Abdelmalek, MF, Loomba, R, Sirlin, CB, and Bashir, M. "Quantifying the Placebo Effect on Liver Fat Using Magnetic Resonance Imaging-Proton Density Fat Fraction in NAFLD Clinical Trials." Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting. San Francisco, CA. November 9, 2018 - November 13, 2018.: WILEY, October 1, 2018.

Scholars@Duke

Pages